[Current status and prospects for targeted therapy for thyroid cancer]

Area of Science:

• Oncology
• Immunology
• Biochemistry

Context:

• Targeted cancer therapy using antibody-drug conjugates faces challenges due to the lack of unique tumor antigens.
• Thyroid cancer lacks identified specific antigens, hindering targeted therapy development.
• Monoclonal antibodies (mAbs) A2B5, HISL-19, and 4F2 bind to specific tumor types, including neuroendocrine and rapidly growing malignant tumors.

Purpose:

• To identify specific antigens for targeted therapy in thyroid cancer.
• To evaluate the potential of monoclonal antibodies A2B5, HISL-19, and 4F2 in treating specific thyroid cancer subtypes.
• To investigate the feasibility of using radiolabeled antibodies for diagnostic and therapeutic purposes.

Summary:

• Immunohistochemical studies revealed that mAbs A2B5 and HISL-19 react specifically with medullary thyroid carcinoma, while mAb 4F2 reacts with anaplastic thyroid carcinoma.
• In vivo studies demonstrated accumulation of 131I-labeled A2B5 in insulinoma (sharing antigens with medullary thyroid carcinoma), suggesting targeted delivery potential.
• Western blotting identified novel HISL-19 and 4F2 antigens in medullary and anaplastic thyroid carcinomas, respectively, which are not found in benign tumors or circulating in blood.

Impact:

• Establishes potential targets (HISL-19 and 4F2 antigens) for developing targeted therapies for medullary and anaplastic thyroid carcinomas.
• Demonstrates the feasibility of using specific monoclonal antibodies for targeted delivery of therapeutic agents to thyroid cancer lesions.
• Paves the way for future research into efficient and effective monoclonal antibody-based chemotherapy for aggressive thyroid cancer subtypes.